PTC Therapeutics, Inc. balance sheet

At the end of fiscal 2025, PTC Therapeutics, Inc. had total assets of $2.90bn, total liabilities of $3.10bn and shareholders' equity of −$205m. It held $985m in cash against $573m of debt: net cash of $412m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

PTC Therapeutics, Inc.: balance sheet, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash and equivalents	28	3	15	50	58	58	112	169	288	209	190	280	594	780	985	509
Receivables	—	—	1	4	11	25	40	68	56	70	110	156	161	159	182	238
Inventory	—	—	—	—	—	0	11	16	19	19	16	22	31	23	80	109
Total current assets	—	5	145	324	356	261	249	321	779	1,232	954	694	1,219	1,366	2,274	2,538
Goodwill	—	—	—	—	—	—	0	82	82	82	82	82	82	82	82	82
Total assets	—	13	152	333	365	269	392	1,119	1,624	2,208	1,938	1,706	1,896	1,705	2,899	3,208
Accounts payable	—	1	1	4	6	6	15	6	10	19	23	27	6	17	45	42
Deferred revenue (current)	—	17	1	3	0	0	4	4	8	4	—	1	1	6	2	2
Total current liabilities	—	28	13	32	45	50	82	167	236	277	509	406	603	581	968	776
Short-term debt	—	4	0	—	—	—	0	12	20	—	150	—	—	—	287	—
Long-term debt	—	0	—	—	92	98	145	141	294	309	282	572	284	285	—	536
Total debt	0	5	0	0	92	98	145	153	314	309	431	572	284	285	573	536
Total liabilities	—	32	15	35	139	150	235	768	1,029	1,726	1,937	2,053	2,714	2,803	3,104	3,399
Shareholders' equity	−239	−100	137	298	226	120	156	351	594	482	1	−347	−819	−1,098	−205	−191
Non-controlling interests and other (assets − liabilities − equity)	—	81	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net debt (negative = net cash)	−28	2	−15	−50	34	40	33	−16	26	100	242	292	−310	−494	−412	27
Shares outstanding	—	—	—	33m	34m	34m	42m	51m	62m	70m	71m	73m	76m	78m	81m	84m

US$ millions unless shown otherwise. Fiscal quarters.

PTC Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Receivables	159	210	196	203	182	220	239	238
Inventory	23	22	34	53	80	76	91	109
Total current assets	1,366	2,316	2,273	2,008	2,274	2,254	2,617	2,538
Goodwill	82	82	82	82	82	82	82	82
Total assets	1,705	2,655	2,634	2,644	2,899	2,869	3,250	3,208
Accounts payable	17	15	27	37	45	25	40	42
Deferred revenue (current)	6	13	10	2	2	0	1	2
Total current liabilities	581	595	628	866	968	924	771	776
Short-term debt	—	—	—	286	287	287	55	—
Long-term debt	285	286	286	—	—	—	536	536
Total debt	285	286	286	286	287	287	591	536
Total liabilities	2,803	2,841	2,841	2,799	3,104	3,050	3,416	3,399
Shareholders' equity	−1,098	−186	−207	−156	−205	−180	−165	−191
Shares outstanding	78m	79m	79m	80m	81m	83m	83m	84m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ACAD vs PTCT LKFT vs PTCT MDGL vs PTCT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from PTC Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to PTC Therapeutics, Inc.